This Saturday’s Wall Street Journal strikes again-providing me ongoing fodder for comment and critique. The article (open colored link to get to it) is titled: A Lower Price Proves to Be Costly For Users of Common Asthma Drug. The particular drug is an inhaled steroid called Flovent HFA. The pharmaceutical company that held the original patent is Gl…
Keep reading with a 7-day free trial
Subscribe to Dr. Kordonowy's Newsletter to keep reading this post and get 7 days of free access to the full post archives.